Under construction – not a live service
Sign in
Taking people in NorwayNo phase

AI Software Tested to Support Stroke Scan Reading in Northern Norway

Tests an AI software tool reading brain scans in adults with ischemic stroke.

Plain-language title generated from the registry record
Registry title: Improving Stroke Care in North-Norway Through Artificial Intelligence

Key facts

Where
Tromsø, NorwaySee the site

Where in Norway

  • University Hospital of North NorwayTromsø, NorwayTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital of North Norway
Trial code
NCT05903898
Record updated
23 July 2025
Original description
Prospective observational multi-center intervention study. The study aims to evaluate whether an artificial intelligence (AI) support tool for radiological image processing (StrokeSens, Circle NVI) can accelerate decision making and increase detection rate in patients with an acute ischemic stroke caused by intracranial large vessel occlusion (LVO) or medium vessel occlusion (MeVO) in Northern Norway. Relevant outcomes will be compared between centres with and without available software during the study period.Read full original descriptionShow less

Improving Stroke Care in North-Norway Through Artificial Intelligence

Prospective observational multi-center intervention study. The study aims to evaluate whether an artificial intelligence (AI) support tool for radiological image processing (StrokeSens, Circle NVI) can accelerate decision making and increase detection rate in patients with an acute ischemic stroke caused by intracranial large vessel occlusion (LVO) or medium vessel occlusion (MeVO) in Northern Norway. Relevant outcomes will be compared between centres with and without available software during the study period.

Inclusion: Patients with acute stroke symptoms admitted to a participating hospital within 24 hours of symptom onset.

Exclusion: Patients not available for follow-up assessments (e.g. non-resident).

ClinicalTrials.gov NCT05903898